THE CHALLENGE
A major unmet need in the opioid overdose response market stems from the rapid rise of synthetic opioids such as fentanyl and the limitations of current antidote delivery solutions. Although naloxone is widely used as an opioid antagonist, existing nasal and injectable formats depend on bystander recognition and manual administration, creating a critical gap when individuals are alone or incapacitated. This reliance on human intervention limits scalability and reduces reliability in high-risk environments such as homes, public spaces, and healthcare transitions. In addition, current systems do not integrate continuous physiological monitoring or automated drug delivery, preventing timely response to overdose events. The short duration of action of naloxone compared to long-acting synthetic opioids also leads to renarcotization, increasing liability concerns for healthcare providers. These technical and operational constraints highlight a market need for autonomous, sensor enabled therapeutic systems capable of rapid detection and sustained intervention to reduce mortality and improve emergency response outcomes.
OUR SOLUTION
This technology introduces a smart transdermal patch designed to address critical gaps in opioid overdose response by combining rapid drug delivery with autonomous detection of fentanyl. The system uses a microneedle-based skin patch built from a biocompatible hydrogel matrix that safely penetrates the outer skin layer and swells upon contact with bodily fluid to enable efficient drug transport. Inside the microneedles are mesoporous silica nanoparticles loaded with naloxone, an opioid antagonist, which are controlled by a fentanyl specific DNA aptamer acting as a molecular switch. When fentanyl is present, the aptamer binds to it and triggers-controlled release of naloxone directly into the bloodstream. This closed loop mechanism enables immediate and repeatable drug dosing without requiring human intervention. From a business perspective, the platform offers a scalable, wearable emergency therapeutics solution that can be used in community settings, clinical environments, and high-risk populations, reducing reliance on emergency response timing and improving survival outcomes.
Figure: In vivo evaluation of iNal showing fentanyl triggered aptamer mediated naloxone release and reversal of opioid overdose in mouse models.
Advantages:
Potential Application: